Amicus Therapeutics Inc
NASDAQ:FOLD
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
9.04
14.52
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Amicus Therapeutics Inc
Amicus Therapeutics Inc
Depreciation & Amortization
Amicus Therapeutics Inc
Depreciation & Amortization Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Depreciation & Amortization | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Amicus Therapeutics Inc
NASDAQ:FOLD
|
Depreciation & Amortization
$8.7m
|
CAGR 3-Years
7%
|
CAGR 5-Years
14%
|
CAGR 10-Years
19%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Depreciation & Amortization
$8.4B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
34%
|
CAGR 10-Years
27%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Depreciation & Amortization
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Depreciation & Amortization
$5.6B
|
CAGR 3-Years
18%
|
CAGR 5-Years
23%
|
CAGR 10-Years
11%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Depreciation & Amortization
$219.7m
|
CAGR 3-Years
22%
|
CAGR 5-Years
17%
|
CAGR 10-Years
13%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Depreciation & Amortization
$469.5m
|
CAGR 3-Years
20%
|
CAGR 5-Years
19%
|
CAGR 10-Years
25%
|
|
Amicus Therapeutics Inc
Glance View
Amicus Therapeutics, Inc. operates as a biotechnology company. The company is headquartered in Philadelphia, Pennsylvania and currently employs 496 full-time employees. The company went IPO on 2007-05-31. The firm's portfolio is Galafold (migalastat), which is the approved oral precision medicine for people living with Fabry disease. Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A (alpha-Gal A) enzyme in patients with genetic variants. Migalastat is approved under the trade name Galafold in the United States, European Union, United Kingdom and Japan. Its biologics program in its pipeline is Amicus Therapeutics GAA (AT-GAA), which is a clinical-stage treatment paradigm for Pompe disease. Pompe disease is a lysosomal disorder (LD) from deficiency in an enzyme, GAA. AT-GAA consists of a uniquely engineered rhGAA enzyme, ATB200, or cipaglucosidase alfa, with an optimized carbohydrate structure to enhance lysosomal uptake, administered in combination with AT2221 (miglustat) that functions as an enzyme stabilizer.
See Also
What is Amicus Therapeutics Inc's Depreciation & Amortization?
Depreciation & Amortization
8.7m
USD
Based on the financial report for Sep 30, 2024, Amicus Therapeutics Inc's Depreciation & Amortization amounts to 8.7m USD.
What is Amicus Therapeutics Inc's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 10Y
19%
Over the last year, the Depreciation & Amortization growth was 25%. The average annual Depreciation & Amortization growth rates for Amicus Therapeutics Inc have been 7% over the past three years , 14% over the past five years , and 19% over the past ten years .
You don't have any saved screeners yet
